Penserra Capital Management LLC Tcr2 Therapeutics Inc. Transaction History

Penserra Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.58 - $8.34 $4,007 - $7,297	-875 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $42 - $91	5 Added 0.57%	875 $7,000
Q2 2021 Aug 12, 2021	BUY	$16.41 - $24.71 $246 - $370	15 Added 1.75%	870 $14,000
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $1,834 - $3,066	90 Added 11.76%	855 $18,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $14,535 - $24,961	765 New	765 $23,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.